| Literature DB >> 35563131 |
Aleksandra Pollap1, Paweł Świt2.
Abstract
Cancer has been one of the most prevalent diseases around the world for many years. Its biomarkers are biological molecules found in the blood or other body fluids of people with cancer diseases. These biomarkers play a crucial role not only in the diagnosis of cancer diseases, but also in risk assessment, selection of treatment methods, and tracking its progress. Therefore, highly sensitive and selective detection and determination of cancer biomarkers are essential from the perspective of oncological diagnostics and planning the treatment process. Immunosensors are special types of biosensors that are based on the recognition of an analyte (antigen) by an antibody. Sandwich immunosensors apply two antibodies: a capture antibody and a detection antibody, with the antigen 'sandwiched' between them. Immunosensors' advantages include not only high sensitivity and selectivity, but also flexible application and reusability. Surface-enhanced Raman spectroscopy, known also as the sensitive and selective method, uses the enhancement of light scattering by analyte molecules adsorbed on a nanostructured surface. The combination of immunosensors with the SERS technique further improves their analytical parameters. In this article, we followed the recent achievements in the field of sandwich SERS immunosensors for cancer biomarker detection and/or determination.Entities:
Keywords: biomarkers; cancer; immunosensors; sandwich sensors; surface-enhanced Raman spectroscopy
Mesh:
Substances:
Year: 2022 PMID: 35563131 PMCID: PMC9105793 DOI: 10.3390/ijms23094740
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Figure 1Exemplary applications of cancer biomarkers for clinical and medical purposes (based on [13,14]).
Figure 2(a) Number of published articles during the period of 2011 to 2022 (February) based on Scopus, ScienceDirect, PubMed, Web of Science, and Google Scholar. (b) Number of biomarker occurrences in the published articles, where: AFP—α-fetoprotein; AFP-L3—lectin-reactive α-fetoprotein; ANG—angiogenin; B7-H6—B7-H6 protein; BLV—bovine leukemia virus antigen gp51; CA 125—carbohydrate antigen 125; CA 19-9—carbohydrate antigen 19-9; CA15-3—cancer antigen 15-3; CA27-29—cancer antigen 27-29; CD19—specific surface marker CD19; CD20—specific surface marker CD20; CD44V6—CD44 variant isoform 6; CEA—carcinoembryonic antigen; CK-19—cytokeratin-19; CTCs—circulating tumor cells; EpCAMs—epithelial cell adhesion molecules; exosomes—tumor-derived exosomes; FER- ferritin; hCE1—human carboxylesterase 1; HE4—human epididymis protein 4; HER2—human epidermal growth factor receptor 2; hK2—human kallikrein 2; IFN-γ—interferon gamma; IL-10—interleukin-10; IL-18—interleukin-18; IL-6—interleukin-6; IL-8—interleukin-8; MMP-7—matrix metalloproteinase-7; MMP-9—matrix metalloproteinase-9; MP—metanephrine; MUC4—mucin protein MUC4; NSE—neuron-specific enolase; OPN—osteopontin; p53—protein p53; PSA—prostate-specific antigen; PSMA—prostate-specific membrane antigen; Rac—adrenal stimulant ractopamine; SCCA—squamous cell carcinoma antigen; TNF-α—tumor necrosis factor α; VEGF—vascular endothelial growth factor.
Figure 3Schematic construction of the sandwich SERS immunosensor in the multiplexed version. The most frequently used approach enabling single-antigen analysis is shown in the red box.
Figure 4Diagram showing the steps of developing a sandwich-type SERS immunosensor: immunoprobe and substrate preparation, and the immunosensor functioning.
Exemplary studies based on different SERS sandwich immunosensor designs for cancer detection resulting in different detection approaches.
| Ref. | Biomarker (Multiplexing Ability) | Single Tag (St)/Dual Tag (Dt) (Raman Reporters) | Nanoparticles (NPs) | Platform | Dynamic Range | LOD |
|---|---|---|---|---|---|---|
| [ | PSA | Colloidal AuNPs | AuNP layer of the patterned substrate | - | - | |
| [ | PSA | Nano-Ag immune probes | Nano-Ag/Au immune substrate | - | 1.8 fg mL−1 | |
| [ | PSA | Silica-coated Ag nanorods (NRs) | Quartz slide with Ag nanorods (NRs) | 0.3 fg mL−1–3 µg mL−1 | 0.3 fg mL−1 | |
| [ | PSA | AuNPs | Magnetic beads (MB) | 50 pg mL−1–200 ng mL−1 | 0.1 ng mL−1 | |
| [ | PSA | Au core–Au shell NPs | Au plate | 10 pg mL−1–10 ng mL−1 | 2.0 pg mL−1 | |
| [ | PSA | ZnO and CoFe2O4 nanocomplexes with Au | Si@Ag substrate | 1 pg mL−1–10 ng mL−1 | 0.65 pg mL−1 | |
| [ | PSA | AgNPs deposited on graphene oxide (GO–AgNP) | Polystyrene 96-well plate substrate | 0.5 pg mL−1–500 pg mL−1 | 0.23 pg mL−1 | |
| [ | PSA | AuNPs | MB | 0.01 ng mL−1–100 ng mL−1 | 0.01 ng mL−1 | |
| [ | PSA | AuNPs | Silver-NP-decorated electrospun polymeric fibers | 1–10 pg mL−1 | 1 pg mL−1 | |
| [ | PSA | Au seeds on Fe3O4@TiO2 core–shell NPs | Ag-coated sandpaper | 10−4–10−12 g mL−1 | 0.014 mM | |
| [ | PSA | AuNPs | Magnetic molecularly imprinted polymers (MMIPs) | 0.5 pg mL−1–1.0 μg mL−1 | 0.9 pg mL−1 | |
| [ | AFP | Hollow gold nanospheres (HGNs) | Gold array | 0–10 ng mL−1 | 0–1 ng mL−1 | |
| [ | AFP | AuNPs | Glass slide modified with AuNPs | 1–100 ng mL−1 | 100 pg/mL | |
| [ | AFP | AgNPs | Molecularly imprinted polymer (MIP) array | 1 ng mL−1–10 µg mL−1 | - | |
| [ | AFP | Core-shell SiO2@Ag | Ag-decorated NiCo2O4 nanorods | 2.1 fg mL−1–2.1 ng mL−1 | 2.1 fg mL−1 | |
| [ | AFP | Ag-covered polystyrene sphere (PS@Ag) | Deposited Si pyramid array (Si@Ag) substrate | 2 fg mL−1–200 ng mL−1 | 1.75 fg mL−1 | |
| [ | AFP | Silica-coated gold/silver core–shell nanostars (AuNS@Ag@SiO2) | Nitrocellulose (NC) membrane | 3 pg mL−1–3 µg mL−1 | 0.72 pg mL−1 | |
| [ | AFP | Nanosphere with a silver coating core (Au@Ag), ultrathin continuous silica (SiO2) shell, and high coverage of gold nanosphere (AuNP) satellites | Nitrocellulose (NC) membrane | 1 fg mL−1–1 ng mL−1 | 0.3 fg mL−1 | |
| [ | AFP | Gold-coated silver nanoparticles (Ag@AuNPs) | Boric-acid-functionalized magnetic silica particles | 1.0 ng mL−1–1.0 mg mL−1 | 1.0 ng mL−1 | |
| [ | AFP | Silver-coated gold nanocubes | Molybdenum disulfide (MoS2) | 1 pg mL−1–10 ng mL−1 | 0.03 pg mL−1 | |
| [ | CEA | HGNs | Magnetic microspheres | 0 ng mL−1–100 ng mL−1 | 10 pg mL−1 | |
| [ | CEA | AuNPs | Au-coated NiFe magnetic nanoparticles (NiFe@Au) | 0 ng mL−1–1 ng mL−1 | 0.1 pM | |
| [ | CEA | AuNPs | γ-Fe2O3@AuNPs | 1 ng mL−1–50 ng mL−1 | 0.1 ng mL−1 | |
| [ | CEA | AuNPs with polydopamine resin (PDR) | Chitosan-stabilized AuNPs on a glassy carbon electrode (GCE) | 1 pg mL−1-100 ng mL−1 | 0.68 pg mL−1 | |
| [ | CEA | AuNPs | Boronate affinity molecularly imprinted polymer (MIP) array | 0.1 ng mL−1–1 mg mL−1 | 0.1 ng mL−1 | |
| [ | CEA | Gold nanostars (AuNSs) | Molecularly-imprinted polymer (MIP) film | 0–1000 ng mL−1 | 1.0 ng mL−1 | |
| [ | CEA | MoS2 nanoflowers@AuNPs | Fe3O4@AuNP-functionalized delaminated Ti3C2Tx MXene-magnetic supporting substrate | 0.0001–100.0 ng mL−1 | 0.033 pg mL−1 | |
| [ | CEA | AuNSs | Screen-printed electrode (Au-SPE) | 0.025–250 ng mL−1 | 0.025 ng mL−1 | |
| [ | SCCA | Gold nanocages (GNCs) | Gold-nanoparticle-coated polydopamine resin microspheres (PDR@GNPs) | 1 × 10−5 M–1 × 10−10 M | 7.16 pg mL−1 | |
| [ | MUC4 | AuNPs | Template-stripped gold (TSG) | 0 μg mL−1–1 μg mL−1 | 33 ng mL−1 | |
| [ | MUC4 | AuNPs | Glass chip with a gold layer | 0.1 μg mL−1–20 μg mL−1 | 0.1 μg mL−1 | |
| [ | IL-6 | AuNPs | Gold/silver nanoshells (Au/AgNSs) | 1 pg mL−1–1 µg mL−1 | 1 pg mL−1 | |
| [ | IL-6 | Ag and AuNPs | Au and Ag hexagonal nanoarray | 0 pg mL−1–1000 pg mL−1 | 25.2 pg mL−1 | |
| [ | IL-8 | GNCs | Highly branched gold nanoparticle (HGNP) substrates | 10 pg mL−1–1 µg mL−1 | 6.04 pg mL−1 | |
| [ | VEGF | AuNSs | Gold triangle nanoarray | 0.1 pg mL−1–10 ng mL−1 | 1.158 ng mL−1 | |
| [ | BLV | Au rods | Magnetic gold NPs (MNP-Au) | 0 mg mL−1–0.06 mg mL−1 | 0.95 µg mL−1 | |
| [ | HE4 | AuNPs | Magnetic core–shell Fe3O4@AuNPs | 1 pg mL−1–10 ng mL−1 | 100 fg mL−1 | |
| [ | HE4 | AuNPs | Gold (Au) nanoplate (NPl) | 0 M–10−9 M | 10−17 M | |
| [ | HER2 | Gold/silver nanoshells | Gold electrode surface | 1 fg mL−1–100 pg mL−1 | 10 fg mL−1 | |
| [ | tumor-derived exosomes | Gold core–silver shell nanorods (Au@AgNRs) | MB | 4.88 × 106–4.88 × 103 | 1200 exosomes | |
| [ | metanephrine | AuNPs | Au films on microscope glass slides | 10−3 M–10−5 M | 10−4 M | |
| [ | p53 | AuNPs | Glass substrate | 10−10 M–10−17 M | 10−15 M | |
| [ | hCE1 | AgNPs | Raspberry-like morphology of Fe3O4@SiO2@AgNP magnetic nanocomposites | 0.1 ng mL−1–1.0 mg mL−1 | 0.1 ng mL−1 | |
| [ | B7-H6 biomarker | Spiky AuNPs | Au thin film modified with a self-assembled monolayer of zwitterionic L-cysteine | 10−10 M–10−14 M | 10−14 M (10.8 fg mL−1) | |
| [ | FER | Gold (Au)-coated ‘stellate’ mesoporous SiO2@Au nanoprobe | Hydrophilic Ag-deposited sandpaper assembled with hydrophobic-treated filter paper (coffee-ring-free hydrophilic–hydrophobic substrate) | 1 × 10−5 g mL−1–3 × 10−13 g mL−1 | 3.16 × 10−14 g mL−1 | |
| [ | MMP-9 | AgNPs | Fe3O4 microspheres (magnetic NPs) | 0 ng mL−1–100 ng mL−1 | 1 pg mL−1 | |
| [ | CA19–9 | Immunoprobe of anti-CA19-9/4-MBA | Au nanowires (NWs) onto Fe3O4@TiO2 matrix | 1000 IU mL−1–0.001 IU mL−1 | 5.65 × 10−4 IU mL−1 | |
| [ | CTCs | Gold–graphene hybrid nanotag (Au–rGO)/gold-reduced graphene oxide nanosystem) | Polycarbonate filter | 1 cell mL−1–100 cell mL−1 | 1 cell mL−1 | |
| [ | ANG, AFP | HGNs | Gold-patterned microarray chip | 0 g mL−1–10−4 g mL−1 | 0.1 pg mL−1 (ANG), 1.0 pg mL−1 (AFP) | |
| [ | CEA, AFP | HGNs | MB | - | - | |
| [ | CEA, AFP | AgNPs | 3D ordered silver nanoshell silica photonic crystal beads (Ag-SPCB) | 0.01 pg mL−1–1000 ng mL−1 (CEA), 0.1 pg mL−1–1000 ng mL−1 (AFP) | 6.6 × 10−6 ng mL−1 (CEA), | |
| [ | CEA, AFP | AuNPs | Gold microelectrode array (GMA) | 0.01 ng mL−1–20 ng mL−1 (CEA), 0.02 ng mL−1 0–5 ng mL−1 (AFP) | 0.3 pg mL−1 (CEA), 0.6 pg mL−1 (AFP) | |
| [ | CEA, AFP | AuNSs | Ordered gold nanohoneycomb arrays | 0.5 ng mL−1–100 ng mL−1 | 0.41 (CEA), 0.35 ng mL−1 (AFP) | |
| [ | CEA, CK-19 | AuNP-coated acid-based resin (AAR) microspheres | Electrode-modified chitosan-stabilized AuNPs | 0.05 ng mL−1–80 ng mL−1 | 0.01 ng mL−1 (CEA), 0.04 ng mL−1 (CK-19) | |
| [ | CA 19-9, MMP-7 | AuNPs | Array of exposed gold ‘wells’ | - | 2.28 pg mL−1 (MMP-7), 34.5 pg mL−1 (CA 19-9) | |
| [ | PSA, Rac | Aggregated AgNPs | 96-Well polystyrene plates | - | 10−9 ng mL−1 (PSA), 10−6 (Rac) ng mL−1 | |
| [ | CEA, NSE | Flowerlike gold NPs | Gold-coated magnetic nanoparticles | 10 pg mL−1–100 ng mL−1 | 1.48 pg mL−1 (CEA), 2.04 pg mL−1 (NSE) | |
| [ | PSA, AFP | AgNPs coated on SiO2 nanospheres (SiO2@Ag) | Gold-film hemisphere array (Au-FHA) immune substrate | 10 fg mL−1–400 ng mL−1 | 3.38 (PSA), 4.87 (AFP) fg mL−1 | |
| [ | CD19, CD20) | AgNPs | MB | 5000 cells mL−1–5 cells mL−1 | 5 cells mL−1 | |
| [ | AFP, AFP-L3 | AuNPs with DSNB | Silicon chips coated with Ag (Si/Ag/MBA) | 0.5 ng mL−1–1000 ng mL−1 | 0.5 ng mL−1 | |
| [ | VEGF, IL-8 | AgNPs | MB | 1.0 fg mL−1–1 ng mL−1 | 1.0 fg mL−1 | |
| [ | SCCA, CA125 | Nano-Ag polydopamine nanospheres (PDA@Ag-NPs) | Nitrocellulose (NC) membrane | 10 pg mL−1–10 µg mL−1 | 7.156 pg mL−1 (SCCA), 7.182 pg mL−1 (CA125) | |
| [ | SCCA, OPN | Au–Ag nanoshuttles (Au–AgNSs) | Hydrophobic filter-paper-based Au nanoflowers (AuNFs) | 10 pg mL−1–10 µg mL−1 | 8.628 pg/mL (SCCA), 4.388 pg/mL (OPN) | |
| [ | SCCA, survivin | Au–Ag nanoshells (Au–AgNSs) | Au–Ag nanobox (Au-AgNB) array substrate | 10 pg mL−1–10 µg mL−1 | 6 pg mL−1 (SCCA), 5 pg mL−1 (survivin) | |
| [ | CEA, AFP, CA 125 | Nanotags with hybrid multilayered nanoshells prepared using layer-by-layer (LBL) assembly of small silver nanoparticles (AgNPs) at the surface of silica (SiO2) particles using poly(ethyleneimine) (PEI) | MB | 0.1 ng mL−1–1 ng mL−1 | 0.1 pg mL−1 | |
| [ | CA 15-3, CA 27-29, CEA | AuNSs | Quartz chip with punched wells | 0.1 ng mL−1–500 ng mL−1 | 0.99 U mL−1 (CA 15-3), 0.13 U mL−1 (CA 27-29), 0.05 ng mL−1 (CEA) | |
| [ | PSA, AFP, CA19-9 | SiO2-coated Si nanoparticles | SiC@Ag substrate (Ag film sputtered on SiC sandpaper) | 0–5 mg mL−1 (PSA, AFP), 0–3 mg mL−1 (CA19-9) | 1.79 fg mL−1 (PSA), 0.46 fg mL−1 (AFP), 1.3 × 10−3 U mL−1 (CA19-9) | |
| [ | PSA, PSMA, hK2 | AgNPs | SiC@Ag@Ag-NPs substrates | 10−5–101 ng mL−1 | 0.46 fg mL−1 (PSA), 1.05 fg mL−1 (PSMA), 0.67 fg mL−1 (hK2) | |
| [ | AFP, CEA, FER | AuNPs | MB | 0.5 pg mL−1–500 pg mL−1 (AFP), 50 pg mL−1–2000 pg mL−1 (CEA), 10 pg mL−1–200 pg mL−1 (FER) | 0.15 pg mL−1 (AFP), 20 pg mL−1 (CEA), 4 pg mL−1 (FER) | |
| [ | PSA, CEA, CA 19-9 | AuNPs | 2D arrays of gold core−silver shell nanoparticles (Au@Ag core–shell NPs) | 1 ng mL−1–1 pg mL−1 (PSA, CEA), 10–40 unit (U) mL−1 (CA19-9) | 1 pg mL−1 (PSA, CEA), 10 unit (U) mL−1 (CA 19-9) | |
| [ | Glypican-1, EpCAMs), CD44V6 | AuNPs | MB | 0–2.3 × 108 particles mL−1 | 2.3 × 106 particles mL−1 | |
| [ | IL-6, IL-8, IL-18 | AuNPs | Ag–Au substrate | 0 ng mL−1–30 ng mL−1 | 2.3 pg mL−1, 6.5 pg mL−1, 4.2 pg mL−1 in a parallel, and 3.8 pg mL−1, 7.5 pg mL−1, 5.2 pg mL−1 in a simultaneous method for IL-6, IL-8 and IL-18, respectively | |
| [ | PSA, AFP, CEA, NSA | AuNPs | Gold substrate modified by Au–S bond (Au–SNBs) | 1 ng mL−1–100 ng mL−1 | 10−12 mol mL−1 | |
| [ | TNF-α, IFN-γ, IL-10, IL-6, IL-8 | AuNPs with silver layers | MB | 0 pg mL−1–105 pg mL−1 (TNF-α) | 4.5 pg mL−1 (TNF-α) |
Explanation of abbreviations: 4-aminobphenyl (ABP), acetamide (AAD), 4-aminothiophenol (ATP), 1,4-benzenedithiol (1,4-BDT), cresyl violet (CV), dimercaptosuccinic acid (DMSA), dual tag (Dt), 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB), 5,5′-dithiobis(succinimidyl-2-nitrobenzoate) (DSNB), fuchsin (FC), graphene oxide (GO), methylene blue (MB), mercaptobenzoic acid (MBA), 4-cyanobenzenethiol (MBN), methoxybenzenethiol (3-MeOBT), malachite green isothiocyanate (MGITC), 4-mercaptophenylboronic acid (MPBA), 2-methoxybenzenethiol (2-MeOBT), monoethylene glycol (MEG-OH), Nile blue A (NBA), 4-nitrobenzenethiol (NBT), 2-naphthalenethiol (2-NT), 4-nitrothiophenol (NTP), rhodamine 6G (R6G), single tag (St), toluidine blue (TB), 2,3,5,6-tetrafluoro-4-mercaptobenzoic acid (TFMBA), thionine (THI), triethylene glycol moiety (TEG–CO2H), tetramethylbenzidine (TMB), X-rhodamine-5-(and-6)-isothiocyanate (XRITC).
Figure 5Schematic representation of microfluidic system combined with SERS for biomarker detection based on antigen–antibody interactions (based on [87]).
Figure 6Schematic representation of lab-on-a-chip platform combined with SERS for biomarker detection based on antigen–antibody interactions (based on [69]).
Figure 7Schematic representation of lateral flow assay combined with SERS for biomarker detection based on antigen–antibody interactions (based on [68]).